Harlan M Krumholz, Mitsuaki Sawano, Bornali Bhattacharjee, César Caraballo, Rohan Khera, Shu-Xia Li, Jeph Herrin, Andreas Coppi, Julie Holub, Yashira Henriquez, Maria A Johnson, Theresa B Goddard, Erica Rocco, Amy C Hummel, Mohammad Al Mouslmani, David F Putrino, Kevin D Carr, Santos Carvajal-Gonzalez, Lawrence Charnas, Magdia De Jesus, Frank W Ziegler, Akiko Iwasaki
INTRODUCTION: Individuals with long COVID lack evidence-based treatments and have difficulty participating in traditional site-based trials. Our digital, decentralized trial investigates the efficacy and safety of nirmatrelvir/ritonavir, targeting viral persistence as a potential cause of long COVID. METHODS: The PAX LC trial (NCT05668091) is a Phase 2, 1:1 randomized, double-blind, superiority, placebo-controlled trial in 100 community-dwelling, highly symptomatic adult participants with long COVID residing in the 48 contiguous US states to determine the efficacy, safety, and tolerability of 15 days of nirmatrelvir/ritonavir compared with placebo/ritonavir...
May 10, 2024: American Journal of Medicine